Amarin CEO John Thero discussing the company's plans for Vascepa, August 2019 — via Bloomberg

December 13, 2019 04:35 PM ESTUpdated 04:55 PM

Amarin wins a blockbuster approval from the FDA. Now everyone can shift focus to the patent

John Carroll

Editor & Founder

For all those people who could never quite believe that Amarin $AMRN would get an expanded label with blockbuster implications, the stress and anxiety …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amarin wins a blockbuster approval from the FDA. Now everyone can shift focus to the patent

John Carroll

Editor & Founder

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Amarin wins a blockbuster approval from the FDA. Now everyone can shift focus to the patent

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings